D-0732-2026 Class I Ongoing
FDA drug recall D-0732-2026 was initiated by JB Chemicals And Pharmaceuticals Ltd on Jun 24, 2026 and is designated Class I. Reason for recall: Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine. The recall status is ongoing. Affected quantity: 34,020 100-count bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 29, 2026
- Initiation Date
- Jun 24, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 34,020 100-count bottles.
Product description
Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-401-10.
Reason for recall
Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.
Distribution pattern
Nationwide in the USA
Code information
Lots: GY825029, GY825030, GY825031, GY825032, expires: 2028-OCT
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0732-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026